With 2 @FDAOncology approved menin-inhibitors, ongoing clinical trials & more approvals on the horizon, it’s more important than ever to accurately identify pts who may benefit from these agents. Come to my talk if you’re at @AMPath I’ll go over testing strategies to identify menin-i-sensitive genotypes in AML A huge thanks to @AMPath @LJTafeMD J. Bryan and the organizers for the invitation. 🙏🏻

Preprint: Isotype Switching Occurs in Germinal Center B Cells and Is Regulated by Interclonal Competition @ShlomchikLab @pitt_immunology papers.ssrn.com/sol3/papers.…

The Fellows of the AACR Academy Cancer Research Impact Grants are one-year, $75,000 awards that support early-career investigators nearing completion of postdoctoral or clinical research training. Apply by June 30. Learn more: brnw.ch/21x3mRq #AACRGrants

Advances in Cancer Immunotherapy for Solid Tumors - Gabizon‐Peretz - Advanced Science - Wiley Online Library advanced.onlinelibrary.wiley…

Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0. Read the full article. bit.ly/3QBApRj

We are looking for motivated postdocs to join our lab starting Spring 2027 to study the Hsp70 Chaperone Code and Proteostasis, see here for more details: trumanlab.org/open-positions

👇

Excellent slides about definition of endocrine resistance and sequencing of endocrine therapy in 2026. From the talk by @AlexEniu @asco #asco26 🙂👍. Money 💰 Slides .

Half of cellular blue nevus are S100 negative but SOX10 positive Potential pitfall and also a clue when evaluating these lesions Dr. Folpe #USCAP2026 #pathology #PathX #PathTwitter

A significant portion of my research has focused on T cells that produce IL-17, known as Th17 cells. We identified distinct subsets that can act as mediators of immune disease, sometimes the “bad guys,” vs regulators that can help restrain inflammation, sometimes the “good guys”

A multivalent VLP-based platform enables peptide-MHC display for precise detection and activation of antigen-specific T cells science.org/doi/10.1126/scia… @ScienceAdvances @hphan95 @ChildrensPhila @SgourakisLab

🫁 Stage I LUAD Risk Score. A simple pathology-based score using 4 high-risk histopathologic features (Grade 3, STAS, VPI, LVI) effectively stratified recurrence risk after R0 resection of stage I invasive non-mucinous LUAD. 5-year DFS: • Low risk: 96.5-98.6% • Intermediate risk: 90.9-91.8% • High risk: 71.7-79.3% A practical tool to guide surveillance and adjuvant therapy discussions. 📖 Lung Cancer DOI 👉🏻 doi.org/10.1016/j.lungcan.20… #CánCare #NSCLC #lcsm #thoraciconcology #lungadenocarcinoma

Hints for the diagnosis of Wilson Disease - Unexplained steatosis/steatohepatitis in a child - Unexplained chronic hepatitis in an adult - Cryptogenic cirrhosis - Cirrhosis with an acute liver failure presentation - Periportal Mallory-Denk bodies but no chronic biliary disease ***Rhodanine stain can be falsely negative*** Dr. Hart #USCAP2026 #pathology #PathX #PathTwitter

"If this is successful, this will open up a new field that will be relevant not just to #melanoma, but many other cancers," said Dr. Shailender Bhatia of Fred Hutch, who was not involved in the study. nbcnews.to/4emvIms

This case was a reminder that lymphoma can really do anything. T-cell lymphoma of the knees! It also raises the question of how to incorporate TP53 mutation into PTCL management. Thanks @NEJM & very glad that the patient is now doing well. nejm.org/doi/full/10.1056/NE… #lymsm

🧬 One mutation. Two completely different stories. The same MYD88 mutation that helps diagnose Waldenström macroglobulinemia can also identify aggressive subsets of diffuse large B-cell lymphoma. But that's only part of the story. Its presence can: ✔ Refine difficult diagnoses ✔ Predict response to BTK inhibitors ✔ Be detected through liquid biopsies ✔ Carry opposite prognostic implications depending on the lymphoma A single molecular alteration with diagnostic, prognostic, and therapeutic impact across multiple lymphoid malignancies. Find out in this month's Gene of the Month: MYD88 Gene, linked here: bit.ly/4o94W5b

🫁 Beyond oligometastatic disease. A new JCO review introduces the concept of metastatic trajectories—tracking how individual lesions respond, evolve, and develop resistance over time. Instead of asking: “Is this patient oligometastatic?” We may soon ask: “Which trajectory is each lesion following?” This framework could refine: ✅ Patient selection for local therapy ✅ Timing of SBRT/surgery/ablation ✅ Systemic therapy adaptation ✅ Precision oncology trial design #LungCancer #NSCLC #ThoracicOncology #RadiationOncology #PrecisionMedicine

Please take a look at this article on Maximizing Impact in Medical Education with Lifestyle Medicine. ow.ly/qJhw50TsCKG The full figure is in the article link. Let me know what you think. #lifestylemedicine #MedED #MedTwitter #faculty #medicalschool

Just out in @LeukemiaJnl 📣 With all hype around #RAS , We thought it’d be cool to characterize BRAF mutations in AML… led by the best collaborators in the business @lindemilesphd @AkEisfeld & teams shorturl.at/Psx9g

MSK research fellow @OrlaFitz10 shared her poster "Tracking genomic evolution in ERBB2-altered biliary tract cancer through longitudinal tumor profiling" during #ASCO26. @ASCO